Last reviewed · How we verify
Isuprel (isoprenaline)
Isuprel (isoprenaline) is a small molecule beta-adrenergic agonist that targets the beta-2 adrenergic receptor. Originally developed in 1956, it is used to treat various conditions including atrioventricular block, cardiac arrest, and low cardiac output syndrome. Isuprel is a non-selective beta-adrenergic agonist, meaning it affects both beta-1 and beta-2 receptors, which can lead to increased heart rate and contractility. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include potential arrhythmias and tachycardia.
At a glance
| Generic name | isoprenaline |
|---|---|
| Drug class | beta-Adrenergic Agonist |
| Target | Beta-2 adrenergic receptor |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1956 |
Approved indications
- Atrioventricular block
- Cardiac arrest
- Common cold
- Hypovolemic shock
- Low cardiac output syndrome
- Syncope due to Heart Block
- Thick Bronchial Secretions
Common side effects
Key clinical trials
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Does Vitamin C Increase the Body Heat Generated By The Nervous System? (NA)
- Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences (PHASE4)
- General Anesthesia vs Local Anesthesia for Endovascular Treatment in Patients With Unruptured Intracranial Aneurysm Using Flow Diverter (NA)
- Early Neurovascular Adaptations in Aging Women (EARLY_PHASE1)
- Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
- Endothelial Dysfunction After SCI
- Autoimmune Basis for Postural Tachycardia Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isuprel CI brief — competitive landscape report
- Isuprel updates RSS · CI watch RSS
- portfolio CI